{"id":"58926be3-9b41-59d0-8836-00b89caf910b","stable_key":"33bef151-bdc7-5892-aff6-0345ab149739:oral-nattokinase-raises-free-amyloid-beta-in-cerebrospinal-fluid","predicate":"increases","statement":"The same treatment increased free-form amyloid-beta in cerebrospinal fluid.","claim_class":"mechanistic","status":"source_derived_draft","evidence_grade":"ungraded","direction":"positive","is_public":true,"mechanism_event_id":"ef31d038-2e50-5728-8243-0bca7c44093b","mechanism_event_label":"The same treatment increased free-form amyloid-beta in cerebrospinal fluid.","subject":{"id":"6b03a125-209a-5060-8b35-ec9e0e54033c","slug":"nattokinase","display_name":"Nattokinase / subtilisin NAT","entity_type_key":"peptide"},"object":{"id":"3e6ba208-0a85-5ba1-bb57-d9c2c8d86a54","slug":"rat-csf-free-amyloid-beta","display_name":"Free-form amyloid-beta concentration in rat cerebrospinal fluid","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"ef31d038-2e50-5728-8243-0bca7c44093b","stable_key":"33bef151-bdc7-5892-aff6-0345ab149739:oral-nattokinase-raises-free-amyloid-beta-in-cerebrospinal-fluid-event","event_type":"observed_intervention","label":"The same treatment increased free-form amyloid-beta in cerebrospinal fluid.","description":"Cerebrospinal fluid","status":"provisional","compartment":null,"participants":[{"entity":{"id":"6b03a125-209a-5060-8b35-ec9e0e54033c","slug":"nattokinase","display_name":"Nattokinase / subtilisin NAT","entity_type_key":"peptide"},"role":"acting component","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"3e6ba208-0a85-5ba1-bb57-d9c2c8d86a54","slug":"rat-csf-free-amyloid-beta","display_name":"Free-form amyloid-beta concentration in rat cerebrospinal fluid","entity_type_key":"cellular_process"},"role":"component the finding is about","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""}]},"contexts":[{"dimension":"duration","value_text":"10 weeks","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"evidence_access","value_text":"Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Rat (40 Wistar in four groups)","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"Nattokinase 65 or 130 mg/kg per day","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Mechanistically ambiguous and recorded as measured rather than interpreted. A rise in free amyloid-beta is consistent with fibril breakdown releasing monomer and with impaired clearance, and this experiment does not distinguish them.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"organism","value_text":"Rat (40 Wistar in four groups)","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"The same treatment increased free-form amyloid-beta in cerebrospinal fluid.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"Effect of Nattokinase in D-galactose- and Aluminum Chloride-induced Alzheimer's Disease Model of Rat. (2024) https://pubmed.ncbi.nlm.nih.gov/39477413/ DOI: 10.21873/invivo.13744","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"route","value_text":"In vivo, oral","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue","value_text":"Cerebrospinal fluid","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"6509dc24-c294-53f2-a69c-3f84c634ddbc","evidence_kind":"source_excerpt","locator":"Lines 1280-1280","start_line":1280,"end_line":1280,"excerpt":"The same treatment increased free-form amyloid-beta in cerebrospinal fluid.","model_system":"Rat (40 Wistar in four groups)","directness":"reported_statement","verification_status":"source_derived_draft","notes":"","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"41cb127c-1c23-53aa-b7d0-5ec7f6fa3c99","stable_key":"import-33bef151-bdc7-5892-aff6-0345ab149739","title":"Nattokinase: what the purified enzyme cleaves, what survives being eaten, and the gap between the two (2026-09-23)","document_type":"imported_text","citation_label":"Original AI-assisted curation built from a supplied entity-first document of 105 entities and 129 claims. Every reference in that document was resolved against live PubMed with its abstract read and its DOI cross-checked on 2026-09-23, and the EFSA novel-food opinion was retrieved and read in full. That check corrected two PMIDs that pointed at unrelated papers, two DOIs, and two papers recorded as carrying no erratum that do carry one; it also reversed three findings the supplied document had stated backwards. Two papers carry a published correction, recorded as such and not as a retraction. Three sources are not indexed in PubMed and are cited by what they have. Laboratory lineages are recorded, so the four papers from one group, the three from another and the two readings of a single applicant dossier cannot be counted as separate lines of support. Study-specific doses, units, populations and limitations retained; activity units are never converted between systems. Not publisher full text.","file_path":"","sha256":"34fc46e0e849d06bfa13cb099a79b50679dd6fd0de8a5a0575326afdde3259c1","revision_id":"efd063e6-e982-5f6e-a4b8-6f2ffe4185ce","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}